Evidence map›Paper›PMID 32343715›Full record

ArticlePloS one2020

The SQSTM1-NUP214 fusion protein interacts with Crm1, activates Hoxa and Meis1 genes, and drives leukemogenesis in mice.

Catherine P Lavau, Waitman K Aumann, Sei-Gyung K Sze, Veerain Gupta, Katelyn Ripple, Sarah A Port, Ralph H Kehlenbach, Daniel S Wechsler

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Advances in the understanding of nuclear pore complexes in human diseases.Journal of cancer research and clinical oncology · 2024
    Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Catherine P LavauDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina, United States of America.
Waitman K AumannAflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, United States of America.
Sei-Gyung K SzeMaine Children's Cancer Program, Scarborough, Maine, United States of America.
Veerain GuptaDepartment of Pediatrics, Duke University Medical Center, Durham, North Carolina, United States of America.
Katelyn RippleDepartment of Pediatrics, Duke University Medical Center, Durham, North Carolina, United States of America.
Sarah A PortDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America.ORCID 0000-0002-1897-0510
Ralph H KehlenbachDepartment of Molecular Biology, Faculty of Medicine and the Göttingen Center for Molecular Biosciences (GZMB), Göttingen, Germany.ORCID 0000-0003-4920-9916
Daniel S WechslerAflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, United States of America.ORCID 0000-0002-8170-862X
Duke Medical Center · USEmory University · USPrinceton University · US

Funding

TRANSFUSION MEDICINE AND RELATED AREAST32HL007057 · NHLBI · DUKE UNIVERSITY · PI Gowthami M Arepally · 1985 to 2026
$10.6M
NHLBI NIH HHS T32 HL007057
6 · The paper itself

Abstract

The NUP98 and NUP214 nucleoporins (NUPs) are recurrently fused to heterologous proteins in leukemia. The resulting chimeric oncoproteins retain the phenylalanine-glycine (FG) repeat motifs of the NUP moiety that mediate interaction with the nuclear export receptor Crm1. NUP fusion leukemias are characterized by HOXA gene upregulation; however, their molecular pathogenesis remains poorly understood. To investigate the role of Crm1 in mediating the leukemogenic properties of NUP chimeric proteins, we took advantage of the Sequestosome-1 (SQSTM1)-NUP214 fusion. SQSTM1-NUP214 retains only a short C-terminal portion of NUP214 which contains FG motifs that mediate interaction with Crm1. We introduced point mutations targeting these FG motifs and found that the ability of the resulting SQSTM1-NUP214FGmut protein to interact with Crm1 was reduced by more than 50% compared with SQSTM1-NUP214. Mutation of FG motifs affected transforming potential: while SQSTM1-NUP214 impaired myeloid maturation and conferred robust colony formation to transduced hematopoietic progenitors in a serial replating assay, the effect of SQSTM1-NUP214FGmut was considerably diminished. Moreover, SQSTM1-NUP214 caused myeloid leukemia in all transplanted mice, whereas none of the SQSTM1-NUP214FGmut reconstituted mice developed leukemia. These oncogenic effects coincided with the ability of SQSTM1-NUP214 and SQSTM1-NUP214FGmut to upregulate the expression of Hoxa and Meis1 genes in hematopoietic progenitors. Indeed, chromatin immunoprecipitation assays demonstrated that impaired SQSTM1-NUP214 interaction with Crm1 correlated with impaired binding of the fusion protein to Hoxa and Meis1 genes. These findings highlight the importance of Crm1 in mediating the leukemogenic properties of SQSTM1-NUP214, and suggest a conserved role of Crm1 in recruiting oncoproteins to their effector genes.

Indexed as

Amino Acid MotifsAnimalsCell LineExportin 1 ProteinGene Expression Regulation, NeoplasticHomeodomain ProteinsKaryopherinsLeukemiaMiceMutagenesis, Site-DirectedMyeloid Ecotropic Viral Integration Site 1 ProteinNeoplasm TransplantationNuclear Pore Complex ProteinsOncogene Proteins, FusionPoint MutationReceptors, Cytoplasmic and NuclearExportin 1 ProteinHomeodomain ProteinsHoxA proteinKaryopherinsMeis1 protein, mouseMyeloid Ecotropic Viral Integration Site 1 ProteinNuclear Pore Complex ProteinsNup214 protein, mouseOncogene Proteins, FusionReceptors, Cytoplasmic and NuclearSequestosome-1 ProteinSqstm1 protein, mouse

Identifiers

PMID32343715
PMCPMC7188244
OpenAlexW3020025754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.